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Summary
Background.  —  Children  with  dilated  cardiomyopathy  in  advanced  heart  failure  may  spend  a  long
time awaiting  heart  transplantation.  Consequently,  mechanical  circulatory  support  is  sometimes
required  as  a  bridge  to  transplantation.  Levosimendan,  a  positive  inotropic  agent,  has  been
reported to  be  safe  and  efﬁcient  for  the  treatment  of  paediatric  heart  failure.
Aims. —  To  report  our  experience  with  levosimendan  in  children  with  decompensated  dilatedBrain  natriuretic cardiomyopathy.
peptide; Methods. —  Paediatric  patients  with  dilated  cardiomyopathy  on  the  transplant  waiting  list  and
Paediatric  heart
transplantation
with criteria  for  mechanical  support  were  included  in  this  single-centred  retrospective  study.
Each patient  received  at  least  one  24-hour  infusion  of  levosimendan  before  mechanical  circu-
latory support  was  considered.  Biological  and  echocardiographic  data  were  analysed.
Abbreviations: BNP, B-type natriuretic peptide; DCM, dilated cardiomyopathy; ECMO, extracorporeal membrane oxygenation; LVEF, left
ventricular ejection fraction; MCS, mechanical circulatory support; VAD, ventricular assist device.
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Results.  —  Six  patients  were  included  over  a  24-month  period.  The  median  age  was  25.5  months
(7.7—34.2 months);  82  infusions  were  performed.  Median  B-type  natriuretic  peptide  concentra-
tion decreased  signiﬁcantly  between  days  0  and  2  (2443  ng/L  [1458—3819  ng/L]  vs  1358  ng/L
[1025—2534  ng/L];  P  =  0.003).  While  only  a  trend  was  noted  in  left  ventricular  ejection  fraction
improvement  (P  =  0.054  by  Simpson’s  method  and  P  =  0.068  by  the  Teicholz  method),  the  subaor-
tic velocity  time  integral  rose  signiﬁcantly  between  days  0  and  8  (12.8  cm/s  [10—14.5  cm/s]  vs
15.3 cm/s  [14.3—16.9  cm/s];  P  =  0.041).
Conclusions.  —  Levosimendan  seems  to  improve  haemodynamics  in  children  with  decom-
pensated dilated  cardiomyopathy;  repeated  infusions  may  delay  the  need  for  mechanical
circulatory  support  while  awaiting  heart  transplantation.  This  therapeutic  agent  should  be
systematically  considered  in  this  setting,  in  addition  to  conventional  inotropic  drugs.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Les  enfants  qui  ont  une  cardiomyopathie  dilatée  en  insufﬁsance  cardiaque  termi-
nale et  qui  sont  sur  liste  de  transplantation  cardiaque  sont  susceptibles  d’attendre  longtemps
un greffon.  Ainsi,  le  recours  à  une  assistance  mécanique  circulatoire  est  parfois  nécessaire
lorsque l’état  du  patient  ne  lui  permet  plus  d’attendre.  Le  levosimendan,  inotrope  positif,  a
précédemment  été  rapporté  sûr  et  efﬁcace  pour  le  traitement  de  l’insufﬁsance  cardiaque  de
l’enfant.
Objectifs.  — Rapporter  notre  expérience  du  levosimendan  chez  des  enfants  avec  cardiomy-
opathie  dilatée  en  insufﬁsance  cardiaque  terminale.
Méthodes.  — Ont  été  inclus,  dans  une  étude  rétrospective  monocentrique,  tous  les  enfants
ayant une  cardiomyopathie  dilatée  sur  liste  de  transplantation  cardiaque  et  avec  des  critères
d’assistance  circulatoire  mécanique.  Avant  la  mise  sous  assistance,  chaque  patient  a  au  moins
rec¸u une  cure  de  levosimendan  de  24  h.  Les  paramètres  biologiques  et  échocardiographiques
ont ensuite  été  analysés.
Résultats.  —  Six  patients  ont  été  inclus  sur  une  période  de  24  mois.  L’âge  médian  était  de
25,5 mois  (7,7—34,2).  Quatre-vingt-deux  infusions  ont  été  réalisées  au  total.  Le  taux  médian  de
BNP diminuait  signiﬁcativement  entre  j0  et  j2  (2443  ng/L  [1458—3819  ng/L]  contre  1358  ng/L
[1025—2534 ng/L]  ;  p  =  0,003).  Alors  que  seule  une  tendance  à  l’amélioration  était  notée
pour la  fraction  d’éjection  ventriculaire  gauche  (p  =  0,054  par  la  méthode  de  Simpson  et
p =  0,068  en  Teicholz),  l’ITV  sous-aortique  augmentait  signiﬁcativement  entre  j0  et  j8  (12,8  cm/s
[10—14,5 cm/s]  contre  15,3  cm/s  [14,3—16,9  cm/s]  ;  p  =  0,041).
Conclusion.  —  En  considérant  la  possibilité  de  perfusions  itératives,  le  levosimendan  semble
améliorer l’état  hémodynamique  de  ces  patients.  Aﬁn  d’attendre  au  mieux  un  greffon  car-
diaque, le  levosimendan  devrait  être  systématiquement  considéré  dans  cette  indication  et  en
association avec  les  traitements  habituels.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
B
D
o
f
P
8
c
r
d
D
D
D
t
a
t
s
p
t
s
aackground
ilated  cardiomyopathy  (DCM),  with  an  annual  incidence
f  0.57  to  0.72  per  100,000  children,  is  the  most  common
orm  of  paediatric  cardiomyopathy  [1,2].  Indeed,  within  the
ediatric  Heart  Transplant  Study  group,  DCM  accounts  for
3%  of  all  paediatric  cardiomyopathy  [3].  This  disease  is
aused  by  a  variety  of  conditions:  idiopathic,  familial,  neu-
omuscular  disorders,  post-myocarditis,  chemotherapeutic
rugs,  metabolic  disorders  and  ventricular  non-compaction.
espite  the  use  of  conventional  therapies,  the  prognosis  for
CM  has  not  changed  appreciably  in  recent  decades  [4].
CM  accounts  for  >  50%  of  indications  for  paediatric  heart
w
h
o
fransplantation  [5],  which  remains  the  gold  standard  ther-
py  for  end-stage  heart  failure.  Because  the  wait  for  a
ransplant  may  be  long,  the  use  of  mechanical  circulatory
upport  (MCS)  is  sometimes  required  as  a  bridge  to  trans-
lantation,  despite  the  use  of  conventional  inotropic  drugs.
Levosimendan,  being  a  calcium  sensitizer  of  cardiac
roponin  and  an  adenosine  triphosphate-sensitive  potas-
ium  agonist,  improves  myocardial  contraction  [6]  and
llows  relaxation  of  the  vascular  smooth  muscle  cells  [7],
hich  are  responsible  for  coronary  vasodilatation.  Maximal
aemodynamic  effects  of  levosimendan  have  been  shown  to
ccur  1—3  days  after  starting  the  infusion  and  are  sustained
or  at  least  a  week.  Although  this  positive  inotropic  agent
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RLevosimendan  and  chronic  heart  failure  
has  been  widely  investigated  in  adults  [8],  only  a  few  studies
have  tested  its  use  in  children  [9].  Nevertheless,  levosimen-
dan  has  been  shown  to  be  safe  and  effective  after  paediatric
cardiac  surgery  [10—12],  especially  in  case  of  low  cardiac
output  syndrome  [13—16].  These  results  have  encouraged
many  European  centres  to  use  levosimendan  routinely  to
prevent  postoperative  low  cardiac  output  syndrome  [17].
In  a  population  of  children  with  DCM  and  chronic  heart  fail-
ure,  the  use  of  levosimendan  was  rarely  reported  [18,19],
despite  a  shared  perception  of  efﬁcacy  among  physicians
who  tried  it  [20].  Finally,  one  study  has  advocated  rotative
inotrope  therapy,  with  levosimendan  infusions,  in  children
with  decompensated  heart  failure  [21].
Because  of  these  promising  results,  levosimendan  has
been  used  frequently  in  our  institution  in  the  past  few  years.
The  aim  of  this  study  was  to  retrospectively  evaluate  the
effects  of  levosimendan  in  children  with  DCM  who  were  on
the  waiting  list  for  heart  transplantation.
Methods
Study design
This  was  a  single-centred  retrospective  study.  Over  a
period  of  24  months  (February  2010—January  2012),  we
enrolled  all  children  with  DCM  in  end-stage  heart  fail-
ure  and  listed  for  heart  transplantation.  Inclusion  criteria
were:  patients  aged  <  18  years,  in  stage  D  according  to
the  last  paediatric  classiﬁcation  of  heart  failure  pro-
posed  by  the  International  Society  of  Heart  and  Lung
Transplantation  [22],  who  were  on  the  waiting  list  for
heart  transplantation,  with,  initially,  indications  for  MCS,
and  who  received  at  least  one  infusion  of  levosimendan
before  they  had  either  a  transplant  or  MCS.  Indications  for
mechanical  assistance—extracorporeal  membrane  oxygena-
tion  (ECMO)  or  any  ventricular  assist  device  (VAD)—were:
left  ventricular  ejection  fraction  (LVEF)  <  30%  (by  the  Tei-
cholz  method  and  Simpson’s  method);  metabolic  acidosis
with  a  pH  ≤  7.30;  and  B-type  natriuretic  peptide  (BNP)
concentration  >  500  ng/L,  despite  continuous  conventional
intravenous  inotropic  support  (milrinone  and  epinephrine).
Patients  with  DCM  but  without  indications  for  MCS  were
excluded  from  the  study.  Biological  and  echocardiographic
data  were  collected  and  analysed  according  to  the  levosi-
mendan  infusions.  Continuation  of  conventional  inotropic
therapies  was  at  the  discretion  of  the  physicians.  All  of  our
patients  with  DCM  receive  angiotensin-converting  enzyme
inhibitors,  beta-blockers  and  diuretics.
Infusions of levosimendan
Because  the  use  of  levosimendan  (Simdax®;  Orion,  Espoo,
Finland)  is  limited  to  exceptional  circumstances  in  France
(a  temporary  certiﬁcate  of  use  is  delivered  by  the  public
health  authorities),  physicians  had  to  obtain  an  informed
consent  form  from  the  parents  before  the  infusions.  The
patients  received  at  least  one  continuous  infusion  of  lev-
osimendan  at  a  dose  of  0.2  g/kg/min  for  24  hours,  without
any  loading  dose.  Use  of  further  infusions  was  at  the  dis-
cretion  of  the  physicians,  on  the  basis  of  clinical,  biological
(BNP  concentration)  and  echocardiographic  arguments.
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easurements  of  BNP  concentration  were  requested  by
hysicians  according  to  their  own  practice.  Depending  on  the
ize  of  the  patient,  venous  samples  were  collected  either
n  1.3  mL  K3 EDTA  microtubes  (Sarstedt,  Nümbrecht,  Ger-
any)  or  in  4  mL  K3 EDTA  BD  Vacutainer® tubes  (Beckton
ickonson,  Franklin  Lakes,  NJ,  USA).  Blood  samples  were
mmediately  transported  to  the  laboratory  after  collection.
NP  concentrations  were  measured  in  whole  blood  by  a  ﬂuo-
escent  immunoassay  method  (Biosite  Diagnostic,  San  Diego,
A,  USA)  on  a  UniCel® DxI  800  system  (Beckman  Coulter,
ullerton,  CA,  USA).  Measurements  were  completed  within
 hours  of  sample  collection.
chocardiographic evaluation
chocardiographic  acquisitions  were  performed  in  the
ame  manner  three  paediatric  cardiologists  experienced  in
chocardiography.  Thus,  for  each  patient,  a  single  echocar-
iogram  was  acquired  daily  by  the  practitioner  who  was
resent  in  the  unit.  All  images  were  acquired  using  a  Vivid
® system  (GE  Healthcare,  Little  Chalfont,  UK).  A  3S-RS  or
 7S-RS  transducer  was  used,  depending  of  the  age  of  the
atient.  LVEF  was  determined  using  two  methods:  the  Tei-
holz  method,  using  the  M-mode  in  a  parasternal  long-axis
iew;  and  the  Simpson’s  method,  in  a  two-dimensional  api-
al  four-chamber  view.  The  subaortic  velocity  time  integral
as  determined  from  an  apical  ﬁve-chamber  view  using
he  Doppler  mode.  Each  echocardiographic  acquisition  was
ransferred  and  recorded  on  our  institution’s  network,  and
as  later  reviewed,  using  EchoPAC® software  (GE  Health-
are,  Little  Chalfont,  UK),  by  a  fourth  cardiologist  who  was
linded  to  the  outcome  of  the  patients.  Because  of  the  ret-
ospective  design  of  the  study,  no  variability  analysis  (intra-
r  intervariability)  was  performed.
tatistical analysis
ll  the  data,  which  were  collected  at  the  time  of  each
nfusion  of  levosimendan,  were  pooled  to  analyse  the  evo-
ution  of  the  different  variables.  All  values  are  expressed  as
he  median  and  ﬁrst  and  third  quartiles.  We  used  a  Mann-
hitney  U  test  to  compare  values.  The  software  package
PSS  for  Windows,  version  17.0  (SPSS  Inc.,  Chicago,  IL,  USA)
as  used  for  statistical  calculations.  P  values  < 0.05  were
onsidered  signiﬁcant.
thics
he  study  was  approved  by  our  local  ethics  committee.  A
ritten  consent  form  was  not  required,  according  to  French
aw,  because  the  studies  were  part  of  the  regular  manage-
ent  of  the  children.  No  examinations  were  performed  only
or  the  purpose  of  the  study.
esultsuring  this  period,  of  the  91  patients  followed  in  our  cen-
re  for  paediatric  DCM,  only  six  were  eligible  for  MCS  and
ere  included.  Table  1  summarizes  the  characteristics  of
350
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Table  1  Patient  characteristics  at  the  time  of  the  ﬁrst  infusion  of  levosimendan.
Patient
no.
Sex  Weight
(kg)
Aetiology  of
DCM
Age  at
diagnosis
Age  at
inclusion
(months)
Inotropic
support
pH  BNP
(ng/L)
Serum
creatinine
(mol/L)
LVEFa
(%)
Subaortic
VTI  (cm/s)
Normal
subaortic  VTI
according  to
age  (cm/s)b
1  M  11.4  Immunological
(maternal
lupus)
Prenatal  37  Milrinone  7.28  6671  38  20  10.8  20.3—26.0
2  M  62  Idiopathic  15  years  182  Milrinone  7.25  3421  85  15  12.8  23.3—29.7
3  F  4  Idiopathic  2  months  2  Milrinone  7.30  4819  28  18  11.7  13.1—18.6
4  M  14.3  Idiopathic  2  years  26  Milrinone  7.26  1415  38  24  12.5  20.1—25.6
5  M  3.3  Idiopathic  2  months  2  Milrinone  7.30  11,878  44  22  13  13.1—18.6
6  F  10  Post-
myocarditis
2  years  25  Dobutamine  7.27  2243  23  21  11.5  20.1—25.6
BNP: B-type natriuretic peptide; DCM: dilated cardiomyopathy; F: female; LVEF: left ventricular ejection fraction; M: male; VTI: velocity time integral.
a Simpson’s method.
b Values of normal aortic VTI are expressed as range ± 1 Z-score; from Pees et al. (2013) [34].
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Table  2  Outcome  of  patients  who  received  iterative  infusions  of  levosimendan.
Patient
no.
No.  of
infusions
Time  between
ﬁrst  infusion
and  MCS/HTx
(days)
Time  at  home
between  ﬁrst
infusion  and
MCS/HTx
(days)
Conventional
inotropic
support
withdrawal
No. of
infusions  of
levosimendan
that  enabled
withdrawal
MCS  (type)  Outcome
1  13  221  54  Yes  1  Yes  (VAD,
18 days)
HTx
2  5  28  0  No  NA  No  HTx
3  16  120  8  Yes  9  Yes  (ECMO,
5 days;  +  VAD,
13 days)
HTx
4  11  108  41  Yes  2  Yes  (VAD,
3 months)
HTx
5  5  258  152  Yes  2  No  Death
(sepsis)
6  32  570  381  Yes  3  No  HTx
ECMO: extracorporeal membrane oxygenation; HTx: heart transplantation; MCS: mechanical circulatory support; NA: not applicable;
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DVAD: ventricular assist device.
the  study  population.  The  median  age  at  inclusion  (i.e.
at  the  time  of  the  ﬁrst  infusion  of  levosimendan)  was
25.5  months  (7.7—34.2  months)  and  the  median  weight  was
10.7  kg  (5.5—13.5  kg).  The  sex  ratio  was  2:1  (four  boys).  At
inclusion,  all  patients  had  a  central  venous  line  and  inotropic
support.  Four  patients  had  a  skin-tunnelled  central  venous
catheter  (patients  1,  3,  5  and  6).  None  of  the  patients  had
respiratory  support  (invasive  or  non-invasive).  The  aetiol-
ogy  of  DCM  was  idiopathic  for  four  patients,  immunological
as  a  result  of  maternal  systemic  lupus  for  one  patient  and
secondary  to  a  myocarditis  (Epstein-Barr  virus)  for  the  last
patient.  The  immunological  cardiomyopathy  had  been  sus-
pected  since  the  foetal  stage  because  of  the  detection  of  an
atrioventricular  block  associated  with  ventricular  dysfunc-
tion  in  the  presence  of  lupic  maternal  antibodies.  Autopsies
of  the  explanted  hearts  conﬁrmed  the  absence  of  myocardi-
tis  lesions  in  the  three  patients  with  idiopathic  DCM  and  who
could  have  been  transplanted.
Infusions of levosimendan
A  total  of  82  24-hour  infusions  were  performed.  The  number
of  infusions  per  patient  is  reported  in  Table  2.  After  the  ﬁrst
infusion,  and  for  all  the  patients,  it  was  always  possible  to
delay  the  need  for  MCS  because  the  criteria  were  no  longer
met.
Effect on BNP concentration
Results  are  reported  in  Table  3.  While  BNP  concentrations
decreased  after  the  infusion  of  levosimendan,  the  lowest
BNP  concentration  was  observed  48  hours  after  the  begin-
ning  of  the  treatment.  The  difference  between  the  BNP
concentrations  was  signiﬁcant  only  between  day  0  and  day
2  (P  =  0.003)  (Fig.  1).  The  difference  between  day  0  and  day
8  was  not  signiﬁcant  (P  =  0.506).
A
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dffect on echocardiographic variables
esults  are  reported  in  Table  3.  LVEF  assessed  either  by
he  Teicholz  method  (TM  mode)  or  by  Simpson’s  method  did
ot  improve  signiﬁcantly  after  the  infusion  of  levosimendan.
nly  a  trend  was  noted  between  day  0  and  day  8  for  each
ethod  (P  = 0.068  and  P  =  0.054,  respectively).  In  contrast,
he  subaortic  velocity  time  integral  improved  signiﬁcantly
etween  day  0  and  day  8  (Fig.  2).
utcomes
ive  patients  were  ﬁnally  transplanted.  Despite  iterative
nfusions  of  levosimendan,  three  of  these  patients  had  MCS
efore  transplantation  (‘bridge  to  transplantation’)  because
he  criteria  were  met  again.  Patients  1  and  4  had  a  ventri-
ular  assist  device  (VAD)  (Berlin  Heart  Excor®, GmbH,  The
oodlands,  USA)  immediately  and  patient  3  had  ECMO  as
rst  intention  before  having  a VAD  5  days  later  (Table  2).
lthough  clinical,  biological  and  echocardiographic  varia-
les  were  stable  after  ﬁve  infusions  of  levosimendan,
atient  5 died  in  our  unit  as  a  result  of  staphylococcal
epsis  (infection  of  the  central  venous  catheter).  For  all
f  the  patients,  median  event-free  survival  (mechanical
ssistance  support,  transplantation  or  death)  was  170  days
111—249  days).  When  considering  only  the  use  of  MCS  (three
atients),  median  survival  was  120  days  (114—170  days).  No
dverse  events  were  reported  or  attributed  to  the  use  of
evosimendan.
iscussion
s  levosimendan  has  been  shown  to  be  effective  in  the  treat-
ent  of  heart  failure  in  different  clinical  situations,  we  have
sed  it  routinely  in  our  unit,  for  many  years,  in  children
ith  decompensated  cardiac  disease.  Because  this  agent
oes  not  increase  oxygen  consumption  of  cardiomyocytes,
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Table  3  Daily  evolution  of  B-type  natriuretic  peptide  concentration  and  echocardiographic  variables  after  infusions  of
levosimendan.
Day  0  Day  1  Day  2 Day  3
BNP  (ng/L)
Median  2443  1733  1358  1781
IQR  1458—3819  933—2758  1025—2534  1175—3502
n  82  72  60  45
LVEF  (%)  (Teicholz)
Median  21  20.3  24  21.5
IQR  18.7—24.9 17—29 20.3—29.3 15.5—26.1
n  58  33  22  10
LVEF  (%)  (Simpson)
Median  21  19  24  24.8
IQR  17.7—27.5  15.3—22  20—27  21.5—26.1
n  40  21  13  5
Subaortic  VTI  (cm/s)
Median  12.8  12.4  12  11
IQR  10—14.5  11.1—13.5  10.4—14.8  9.2—12.3
n  69  35  23  15
Day  4  Day  5  Day  6  Day  7  Day  8
BNP  (ng/L)
Median  1684  1745  1730  1722  1808
IQR  1185—3595  1119—3476  1276—3942  1279—3389  1341—3832
n  55  46  54  47  21
LVEF  (%)  (Teicholz)
Median  23  23.2  21.5  21  23.1
IQR  18.3—24.5  19.8—24.2  18.3—25.6  18.7—25.8  20—29.6
n  11  11  18  16  9
LVEF  (%)  (Simpson)
Median  20.3  23  23.2  23.7  28
IQR  13.5—25.1  16.5—27  17.2—27.2  21.1—29.9  28.6
n  7  9  14  11  7
Subaortic  VTI  (cm/s)
Median  10.9  11.5  12.3  12.9  15.3
IQR  9.5—12.1 8.7—13.1 10—15  9.1—14.3  14.3—16.9
n  14  19  21  18  35
BNP: B-type natriuretic peptide; IQR: interquartile range; LVEF: left ventricular ejection fraction; VTI: velocity time integral.
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ot  appears  to  be  an  emerging  tool  for  the  treatment  of  pae-
iatric  heart  failure  [9,18—20].  Although  Suominen  et  al.
eported  the  good  perception  of  physicians  who  used  levosi-
endan  in  a  paediatric  population  [20], no  previous  study
as  analysed  the  effect  of  levosimendan  on  biological  and
chocardiographic  variables  in  a  population  of  children  with
CM  in  end-stage  heart  failure.  We  believe  that  levosimen-
an,  by  exercising  beneﬁcial  effects  on  cardiac  function,
s  efﬁcient  in  delaying  the  need  for  MCS.  Indeed,  criteria
or  MCS  were  no  longer  met,  temporarily  at  least,  after
he  ﬁrst  use  of  levosimendan.  When  considering  mechanical
ssistance  and  heart  transplantation,  our  patients  beneﬁted
rom  >  3  additional  months  without  the  need  for  MCS  while
aiting  for  a  transplant  (although  some  required  ECMO  or
 VAD,  ultimately).  While  the  wait  for  a  heart  transplant
inherently  uncertain)  may  be  long,  this  gain  in  time  is
xtremely  valuable  for  patients.  As  morbidity  and  mortal-
ty  have  been  shown  to  be  correlated  to  the  duration  of
m
o
bechanical  assistance,  every  day  ‘free  from  assistance’  is
ighly  beneﬁcial  [23].
BNP  concentration  is  well  correlated  with  New  York  Heart
ssociation  class  in  children  with  heart  failure  (either  in
he  context  of  congenital  heart  disease  or  cardiomyopa-
hy),  and  this  biological  marker  has  been  found  to  be
seful  in  monitoring  these  patients  [24]. In  adults  with
dvanced  heart  failure,  levosimendan  has  been  shown  to
e  more  effective  than  furosemide  infusion  at  improving
NP  concentration  [25].  We  also  demonstrated  that  BNP
as  signiﬁcantly  decreased  after  an  infusion  of  levosimen-
an.  For  our  patients,  this  effect  was  greatest  on  day  2  after
he  infusion.  In  contrast,  there  was  no  signiﬁcant  improve-
ent  in  LVEF,  which  may  be  a  reﬂection  of  the  small  size
f  our  cohort.  Variability  in  M-Mode  and  two-dimensional
easurements,  which  can  reach  15%  [26],  may  also  explain
ur  ﬁndings.  The  aortic  velocity  time  integral,  which  has
een  found  to  be  reliable  for  the  extrapolation  of  cardiac
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Figure 1. Daily evolution of B-type natriuretic peptide (BNP)
concentration according to the infusion of levosimendan in a pop-
ulation of children with dilated cardiomyopathy in end-stage heart
failure. A. The evolution of BNP concentration shows a minimal
value on day 2 after the infusion and a persisting effect until day 8.
B. The difference in BNP concentration is signiﬁcant between day 0
(D0) and day 2 (D2). Boxes represent ﬁrst and third quartiles, hor-
izontal lines represent medians and whiskers indicate 10th—90th
Figure 2. Daily evolution of subaortic velocity time integral (VTI)
according to the infusion of levosimendan in a population of chil-
dren with dilated cardiomyopathy in end-stage heart failure. The
improvement in subaortic VTI value was signiﬁcant between day 0
(D0) and day 8 (D8) after the infusion. Boxes represent ﬁrst and third
quartiles, horizontal lines represent medians and whiskers indicate
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upercentiles. Circles represent outliers. A Mann-Whitney U test was
used to compare the medians.
index  in  children  [27,28],  was  signiﬁcantly  improved  until
day  8  after  the  infusions.  This  observation  is  consistent  with
a  previous  study  that  advocated  a  rotative  inotrope  ther-
apy  involving  repeated  levosimendan  infusions  in  addition
to  conventional  inotropic  agents  for  children  with  decom-
pensated  heart  failure  [21].  Because  its  active  metabolite,
OR-1896,  has  a  long  elimination  half-life,  levosimendan  has
a  long-lasting  effect  of  few  days,  making  iterative  infusions
interesting  [29].  However,  these  effects  seemed  to  decrease
over  the  time.  Indeed,  physicians  had  the  impression  that
subsequent  infusions  were  less  effective  after  a  few  months.
In  their  recent  meta-analysis,  Delaney  et  al.  showed
that,  compared  with  dobutamine,  levosimendan  improved
the  survival  of  adults  with  acute  severe  heart  failure  [30].
However,  this  ﬁnding  was  probably  the  result  of  a  higher
mortality  rate  associated  with  the  use  of  dobutamine,
rather  than  a  real  reduction  in  the  mortality  rate  associ-
ated  with  levosimendan.  Indeed,  compared  with  placebo,
levosimendan  did  not  signiﬁcantly  reduce  the  mortality
rate.  Although  randomized  trials  in  a  general  population
of  adult  patients  with  acute  severe  heart  failure  failed
to  show  a  correlation  between  the  haemodynamic  efﬁcacy
s
a
t
b0th—90th percentiles. A Mann-Whitney U test was used to compare
he medians.
f  the  drug  and  a  sustained  survival  beneﬁt,  the  value
f  levosimendan  in  targeted  populations  (such  as  DCM  in
nd-stage  heart  failure)  remains  to  be  studied  speciﬁcally.
hile  randomized  trials  included  patients  with  both  acute
nd  chronic  heart  failure,  only  one  infusion  was  performed
o  compare  levosimendan  with  other  inotropic  drugs.  The
eterogeneity  of  the  cohorts  seems  to  be  a  major  pit-
all  of  these  studies.  The  inevitable  progression  of  certain
ardiopathies  should  not  be  compared  with  acute  and,  some-
imes,  reversible  causes  of  heart  failure.  Similarly,  the
reatment  may  vary  according  to  the  disease.  Hence,  lev-
simendan  should  be  reused  to  treat  chronic  heart  failure
fﬁciently,  even  if  there  is  a  potential  loss  of  efﬁcacy  over
he  time.  This  attenuation  of  haemodynamic  effects  was
hown  previously  by  Hitz  et  al.,  who  reported  the  case
f  a  14-year-old  boy  with  DCM  who  was  treated  success-
ully  with  levosimendan  until  transplantation  [31].  Apart
rom  this  intra-individual  variability  in  efﬁciency,  which  is
robably  related  to  the  natural  course  of  the  heart  dis-
ase,  there  is  obviously  an  interindividual  variability  in
evosimendan  effects.  This  difference,  observed  between
atients  with  the  same  cardiopathy,  allows  differentiation
etween  responders  and  non-responders.  In  a  study  that
xamined  the  haemodynamic  effects  of  levosimendan  in
dult  patients  with  borderline  right  ventricular  function
efore  left  VAD  implantation,  a  reduction  in  N  terminal
ro-BNP  concentration  of  <  25%  from  baseline  values  was  sig-
iﬁcantly  associated  with  worse  outcomes  (caused  by  severe
ight  ventricular  dysfunction)  [32].  Moreover,  Farmakis  et  al.
howed,  in  a  population  of  acute  decompensated  heart  fail-
re,  that  the  BNP  response  to  therapy  was  correlated  with
urvival  [33].  Indeed,  patients  with  a  BNP  change  >  58%  had better  6-month  survival  than  patients  with  a  BNP  reduc-
ion  <  58%.  Therefore,  levosimendan-induced  BNP  reduction,
eing  an  independent  predictor  of  mid-term  outcome,  may
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otentially  identify  patients  who  might  beneﬁt  from  a  strat-
gy  of  multiple  levosimendan  infusions.
tudy limitations
he  main  limitation  of  our  study  lies  in  its  retrospective  and
bservational  aspect.  Indeed,  we  did  not  have  any  control
roup  to  compare  the  evolution  of  such  children  without
evosimendan  infusions.  Thus,  the  decision  to  use  MCS  was
ade  by  the  physicians  according  to  the  usual  clinical,
iological  and  echocardiographic  arguments.  Nevertheless,
efore  the  beginning  of  the  infusions,  all  the  patients  were
ligible  for  MCS.  Because  our  patients  were  unresponsive  to
onventional  intensive  medical  management,  levosimendan
ndoubtedly  allowed  MCS  to  be  delayed.  Finally,  the  small
ize  of  our  cohort  may  explain  why  the  median  BNP  values
ad  large  standard  deviations.  This  lack  of  statistical  power
s  possibly  also  responsible  for  the  absence  of  signiﬁcant  LVEF
mprovement.
There  is  a  lack  of  randomized  controlled  studies  on  the
se  of  levosimendan  in  children,  and  further  studies  are
eeded  to  conﬁrm  these  results.  Because  there  are  still  no
fﬁcial  indications  for  its  prescription  in  paediatric  patients,
evosimendan  was  used  as  a  rescue  drug  for  our  children,
hich  means  that  it  was  only  used  in  the  ﬁnal  stage  of  the
ardiac  disease.  In  DCM,  earlier  administration  may  make  it
ossible  to  further  delay  the  ineluctable  decline  in  cardiac
ell  properties.  To  optimize  the  use  of  this  new  therapeutic
gent,  objective  criteria  (clinical,  biological  and  echocar-
iographic)  for  its  delivery  remain  to  be  determined.
onclusion
evosimendan  seems  to  improve  haemodynamics  in  children
ith  DCM  in  end-stage  heart  failure.  In  such  critical  patients,
he  use  of  this  positive  inotropic  agent  facilitates  the  wait
or  heart  transplantation.  Indeed,  repeated  infusions  of  lev-
simendan  may  allow  several  months  to  be  spent  without
he  need  for  MCS.  In  the  context  of  advanced  paediatric
eart  failure,  our  study  suggests  the  systematic  use  of  lev-
simendan,  in  addition  to  conventional  medications.  Further
rospective  randomized  studies  are  needed  to  conﬁrm  these
reliminary  results.
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